The Effect of Antrum Size on Weight Loss, Glucagon-Like Peptide-1 (GLP-1) Levels, and Glycemic Control Following Laparoscopic Sleeve Gastrectomy in Adolescents with Obesity and Type 2 Diabetes.

Plain-language guide to PMID 34355337 (2021): randomized controlled trial of Glucagon in 36 adolescents, fat loss, obesity & body recomposition.

Key Facts

PMID: 34355337
Journal: Obesity surgery
Year: 2021
Study type: Randomized Controlled Trial
Authors: Shehata MA et al. (4 authors)
DOI: 10.1007/s11695-021-05590-9
Registered trial: NCT04388059

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Glucagon in the context of fat loss, obesity & body recomposition, published as a randomized controlled trial.

The aim of this study was to compare the effect of antral resection versus antral preservation sleeve gastrectomy on the post-operative GLP-1, glycemic control, and weight loss in adolescents suffering from severe obesity and type 2 diabetes (T2D).

Who Took Part

The abstract describes 36 adolescents taking part.

PubMed indexes the participants as teenagers.

Patients were randomly divided into 2 groups: group (A) and group (B).

Each group included 18 patients who underwent LSG, starting transection at 2 cm or 5 cm from the pyloric ring in group (A) and group (B), respectively.

How the Study Was Run

The researchers set it up as a randomized study.

The adolescents were allocated by chance, so the Glucagon group and the comparison group should start out alike.

This study included 36 adolescents.

They were followed up at 1, 3, 6, 12, and 24 months post-operatively.

The outcomes were the post-operative GLP-1 response, glycemic control, weight loss, and safety.

What Was Measured

Topics PubMed links to this paper include Body Mass Index, Diabetes Mellitus, Type 2, Gastrectomy, Glucagon-Like Peptide 1, Glycemic Control, Laparoscopy and Obesity, Morbid.

Author keywords: Adolescent, Antral preservation, Antral resection, C-peptide, GLP-1 and Laparoscopic sleeve gastrectomy.

What This Means in Plain Language

The paper is a randomized study of Glucagon in 36 adolescents in people with fat loss, obesity & body recomposition.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Obesity surgery), a journal based in United States.

More context: the Glucagon compound page, Fat loss, obesity & body recomposition research.

Our Notes on the Compound

Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.